Drug Information

Drug General Information
Drug ID
D05CHR
Former ID
DIB014947
Drug Name
LBY-135
Synonyms
LCR-211; Anti-DR5 agonist chimerics mAb (cancer), Novartis; Anti-death receptor5 agonist chimeric monoclonal antibody (cancer), Novartis
Drug Type
Antibody
Indication Solid tumours [ICD9: 140-199, 210-229; ICD10:C00-D48] Discontinued in Phase 1 [548517]
Company
Novartis AG
Target and Pathway
Target(s) Tumor necrosis factor receptor superfamily member 10B Target Info [532312]
KEGG Pathway Cytokine-cytokine receptor interaction
p53 signaling pathway
Apoptosis
Natural killer cell mediated cytotoxicity
Measles
Influenza A
NetPath Pathway TCR Signaling Pathway
TNFalpha Signaling Pathway
PANTHER Pathway Apoptosis signaling pathway
p53 pathway
Pathway Interaction Database TRAIL signaling pathway
Direct p53 effectors
Caspase Cascade in Apoptosis
Reactome Ligand-dependent caspase activation
Regulation by c-FLIP
RIPK1-mediated regulated necrosis
CASP8 activity is inhibited
Dimerization of procaspase-8
TRAIL signaling
WikiPathways DNA Damage Response
Apoptosis-related network due to altered Notch3 in ovarian cancer
Apoptosis
miR-targeted genes in squamous cell - TarBase
miR-targeted genes in muscle cell - TarBase
miR-targeted genes in lymphocytes - TarBase
miR-targeted genes in epithelium - TarBase
Extrinsic Pathway for Apoptosis
Apoptosis Modulation and Signaling
miRNA Regulation of DNA Damage Response
References
Ref 548517Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800026275)
Ref 532312Safety, pharmacokinetics, and pharmacodynamics of the DR5 antibody LBY135 alone and in combination with capecitabine in patients with advanced solid tumors. Invest New Drugs. 2014 Feb;32(1):135-44.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.